biote Corp. (NASDAQ:BTMD – Get Free Report) CFO Robert Charles Peterson sold 11,376 shares of the stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $7.57, for a total transaction of $86,116.32. Following the sale, the chief financial officer now owns 32,874 shares of the company’s stock, valued at approximately $248,856.18. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
biote Stock Up 1.3 %
NASDAQ:BTMD opened at $8.10 on Friday. The firm has a market cap of $502.49 million, a PE ratio of 73.64 and a beta of 0.98. The company’s 50-day moving average price is $6.69 and its two-hundred day moving average price is $5.72. biote Corp. has a 12 month low of $3.65 and a 12 month high of $8.29.
biote (NASDAQ:BTMD – Get Free Report) last announced its earnings results on Tuesday, May 7th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.05 by $0.18. biote had a negative return on equity of 36.67% and a net margin of 4.30%. The business had revenue of $46.80 million for the quarter, compared to the consensus estimate of $47.09 million. On average, research analysts expect that biote Corp. will post 0.56 EPS for the current fiscal year.
Institutional Trading of biote
biote Company Profile
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Read More
- Five stocks we like better than biote
- What Does a Stock Split Mean?
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- Which Wall Street Analysts are the Most Accurate?
- This Financial Stock’s Earnings Signal a Buying Opportunity
- The 3 Best Retail Stocks to Shop for in August
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.